Rallybio (RLYB) announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic study evaluating RLYB116, the company’s innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor. Additionally, Rallybio announced that the initial indication focus for RLYB116 will be on two hematologic conditions with significant unmet need: immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Patients suffering from these potentially life-threatening conditions have no approved or effective therapeutic options.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLYB: